Coronavirus Disease 2019
Conditions
Interventions
NIMRCAF
Covidol
Bupiji Oil
Standard Care for COVID19
Sponsors
Kilimanjaro Clinical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Confirmed COVID-19 patients aged eighteen years and above • Hospitalized and with moderate or severe form of disease, during the study period at any of the study sites • Consented participant
Exclusion criteria
Exclusion criteria: • Unconsented participant • Patient with any clinically significant Grade 3 or 4 laboratory abnormality according to the Division of AIDS (DAIDS) grading scale • Patient aged less than eighteen years • Patient with peptic ulcers • History of using any of the investigational herbal preparations • Pregnant women • COVID-19 patients with mild signs and symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the frequency, severity, and duration of adverse events. The number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events will be evaluated through study completion. | — |
Secondary
| Measure | Time frame |
|---|---|
| NIMRCAF, Covidol or Bupiji oil preparation will be declared to have efficacy on the management of the COVID-19 during the observational period through: • Reduction of number of corona virus as measured CT value • Duration of hospitalization • Duration of clearance of the presenting signs and symptoms • Mortality | — |
Countries
United Republic of Tanzania
Contacts
Public ContactDorica Burengelo
National Institute for Medical Research Muhimbili Center
Outcome results
None listed